CD276 and cancer: Here, we demonstrate that high mTORC1 activity together with CD276 expression is associated with poor overall survival and immunosuppressive phenotypes in The Cancer Genome Atlas (TCGA) pan-cancer cohort (over 10,000 patients, across 34 different cancer subtypes).